JPMorgan analyst Anupam Rama downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Neutral to Underweight.
The analyst comments: "We are moving to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE